Cited by 1,544Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Open access

Saag, Kenneth G., Petersen, Jeffrey, Brandi, Maria Luisa, Karaplis, Andrew C., Lorentzon, Mattias, Thomas, Thierry, Maddox, Judy, Fan, Michelle, Meisner, Paul D., Grauer, Andreas·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1708322

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1708322

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citation
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citation
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citation
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011

Show all 31 references

Sorted by citations

Items 401–500 of 1,000

Secondary Fracture Rate After Vertebral Osteoporotic Compression Fracture Is Decreased by Anti-Osteoporotic Medication but Not Increased by Cement Augmentation
Mills, E. S., Hah, R. J., Fresquez, Z. A., Mertz, K. C., Buser, Z., Alluri, R. K., & Anderson, P. A. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00469 · Cited by 27
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Fuggle, N. R., Al‐Daghri, N. M., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M. P. T., Giusti, A., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02272-z · Cited by 28
Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure
Jung, J., Ryu, J., Shim, G., & Kwon, Y. (2023) · Clinical Oral Implants Research · doi:10.1111/clr.14144 · Cited by 28
Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Dimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 28
Romosozumab to rebuild the foundations of bone strength
Ferrari, S. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.5 · Cited by 27
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
Body, J., Marín, F., Kendler, D. L., Zerbini, C. A. F., López‐Romero, P., Moericke, R., Casado, E., Fahrleitner‐Pammer, A., Stepan, J. J., Lespessailles, É., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05463-4 · Cited by 27
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 27
Romosozumab — Promising or Practice Changing?
Rosen, C. J. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711298 · Cited by 27
Genetic activation of glycolysis in osteoblasts preserves bone mass in type I diabetes
Ji, X., Seeley, R. A., Li, K., Song, F., Liao, X., Song, C., Angelozzi, M., Valeri, A., Marmo, T., Lee, W., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.003 · Cited by 28
Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women
Hong, N., Shin, S., Kim, H.-J., Cho, S., Park, J., & Rhee, Y. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae179 · Cited by 26
Sequential and Long-term Therapy for Osteoporosis
McClung, M. R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00909-2 · Cited by 26
Advances and Unmet Needs in the Therapeutics of Bone Fragility
Ramchand, S. K., & Seeman, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00505 · Cited by 26
Bone-modifying Agents (BMAs) in Breast Cancer
Shapiro, C. L. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.04.009 · Cited by 26
Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases
Miedany, Y. M. E., Abu-Zaid, M. H., Gaafary, M. M. E., Naby, M. M. H. E., Fathi, N. A., Saber, H. G., Hassan, W. A., Eissa, M., Mohannad, N., Khaled, H. F., et al. (2021) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00056-9 · Cited by 26
Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: their impact on the biology of fusion and systematic review of the literature
Bryant, J.-P., Perez-Roman, R. J., Burks, S. S., & Wang, M. Y. (2021) · Neurosurgical FOCUS · doi:10.3171/2021.3.focus201049 · Cited by 26
Which treatment to prevent an imminent fracture?
Iconaru, L., Baleanu, F., Charles, A., Mugisha, A., Benoit, F., Surquin, M., Karmali, R., Body, J.-J., & Bergmann, P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101105 · Cited by 26
Sclerostin Inhibition
Aditya, S., & Rattan, A. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_106_20 · Cited by 26
The effect of osteoporosis treatment on bone mass
Appelman‐Dijkstra, N. M., Oei, H. L. D. W., Veldhuis‐Vlug, A. G., & Winter, E. M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101623 · Cited by 27
Diabetes and bone
de Araújo, I. M., Moreira, M. L. M., & de Paula, F. J. A. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000552 · Cited by 26
Evaluation of Risk of Cardiac or Cerebrovascular Events in Romosozumab Users Focusing on Comorbidities: Analysis of the Japanese Adverse Drug Event Report Database
Kotake, K., Mitsuboshi, S., Omori, Y., Kawakami, Y., & Kawakami, Y. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221144960 · Cited by 26
Defining Very High Fracture Risk: Is FRAX Fit for Purpose?
Compston, J. E., & Drake, M. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4134 · Cited by 26
Risk factors for imminent fractures: a substudy of the FRISBEE cohort
Iconaru, L., Moreau, M., Baleanu, F., Kinnard, V., Charles, A., Mugisha, A., Surquin, M., Benoit, F., Karmali, R., Paesmans, M., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05772-8 · Cited by 26
Bone Health in Patients With Type 2 Diabetes
Forner, P. M., & Sheu, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae112 · Cited by 25
Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis
McClung, M. R., Betah, D., Leder, B. Z., Kendler, D. L., Oates, M. K., Timoshanko, J., & Wang, Z. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae194 · Cited by 25
Clinical practice guideline: The diagnosis and treatment of osteoporosis
Thomasius, F. E., Kurth, A., Baum, E., Drey, M., Maus, U. M., & Schmidmaier, R. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0222 · Cited by 25
Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study
McCloskey, E. V., Johansson, H., Harvey, N. C., Lorentzon, M., Shi, Y., & Kanis, J. А. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05815-0 · Cited by 25
Self-citation
Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report
Uehara, M., Nakamura, Y., Nakano, M., Miyazaki, A., Suzuki, T., & Takahashi, J. (2021) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxab018 · Cited by 25
The WNT1G177C mutation specifically affects skeletal integrity in a mouse model of osteogenesis imperfecta type XV
Vollersen, N., Zhao, W., Rolvien, T., Lange, F., Schmidt, F. N., Sonntag, S., Shmerling, D., Kroge, S. V., Stockhausen, K. E., Sharaf, A. L., et al. (2021) · Bone Research · doi:10.1038/s41413-021-00170-0 · Cited by 25
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions
Ahmad, S. S., Ahmed, F., Ali, R., Ghoneim, M. M., Alshehri, S., Najmi, A. K., Ahmad, S., Ahmad, M. Z., Ahmad, J., & Khan, M. A. (2022) · Immunotherapy · doi:10.2217/imt-2021-0282 · Cited by 25
Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy
Zhang, A. S., Khatri, S., Balmaceno-Criss, M., Alsoof, D., & Daniels, A. H. (2022) · Spine Deformity · doi:10.1007/s43390-022-00621-6 · Cited by 25
Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5
Diegel, C. R., Krämer, I., Moes, C., Foxa, G. E., McDonald, M. J., Madaj, Z., Guth, S., Liu, J., Harris, J. L., Kneissel, M., et al. (2023) · Bone Research · doi:10.1038/s41413-023-00278-5 · Cited by 25
Romosozumab — on track or derailed?
Khosla, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.136 · Cited by 25
Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis
Ye, W., Wang, Y., Mei, B., Hou, S., Liu, X., Wu, G., Qin, L., Zhao, K., & Huang, Q. (2018) · Bone · doi:10.1016/j.bone.2018.01.001 · Cited by 25
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
Langdahl, B. L., & Andersen, J. D. (2018) · Journal of Bone Metabolism · doi:10.11005/jbm.2018.25.3.133 · Cited by 25
Current Status of Bone-Forming Therapies for the Management of Osteoporosis
Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00675-8 · Cited by 25
Emerging therapeutic targets for osteoporosis
Gennari, L., Merlotti, D., Falchetti, A., Eller-Vainicher, C., Cosso, R., & Chiodini, I. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1726889 · Cited by 25
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective
Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.02.004 · Cited by 25
The Role of Bone Biopsy in the Management of CKD-MBD
an initiative of the CKD-MBD working group of the ERA-EDTA the European Renal Osteodystrophy (EUROD), Ferreira, A. C., Cohen-Solal, M. E., D’Haese, P. C., & Ferreira, A. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00838-z · Cited by 25
Immunomodulatory nanomedicine for osteoporosis: Current practices and emerging prospects
Luo, Y., Liu, H., Chen, M., Zhang, Y., Zheng, W., Wu, L., Liu, Y., Liu, Y., Luo, E., & Liu, X. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.03.011 · Cited by 24
The potential effect of romosozumab on perioperative management for instrumentation surgery
Ishikawa, K., Tani, S., Toyone, T., Tsuchiya, K., Towatari, T., Oshita, Y., Yamamura, R., Wada, K., Nagai, T., Shirahata, T., et al. (2024) · JOR Spine · doi:10.1002/jsp2.1356 · Cited by 24
Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data
Ding, L., Wen, F., Wang, H., Wang, D.-H., Liu, Q., Mo, Y., Tan, X., Qiu, M., & Hu, J.-X. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05183-4 · Cited by 24
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
Cosman, F., Libanati, C. R., Deignan, C., Yu, Z., Wang, Z., Ferrari, S., Jensen, J. B., Peris, P., Bertoldo, F., Lespessailles, É., et al. (2021) · JBMR Plus · doi:10.1002/jbm4.10546 · Cited by 25
Guideline No. 422g: Menopause and Osteoporosis
Khan, A. A., Alrob, H. A., Ali, D. S., Dandurand, K., Wolfman, W., & Fortier, M. P. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.09.013 · Cited by 24
Summary of the Thai Osteoporosis Foundation (TOPF) Clinical Practice Guideline on the diagnosis and management of osteoporosis 2021
Charatcharoenwitthaya, N., Jaisamrarn, U., Songpatanasilp, T., Kuptniratsaikul, V., Unnanuntana, A., Sritara, C., Nimitphong, H., Wattanachanya, L., Chotiyarnwong, P., Amphansap, T., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.001 · Cited by 25
Osteoporosis: Spotlight on current approaches to pharmacological treatment
Sindel, D. (2023) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2023.13054 · Cited by 24
Therapeutic Prediction of Osteoporotic Vertebral Compression Fracture Using the AO Spine-DGOU Osteoporotic Fracture Classification and Classification-Based Score: A Single-Center Retrospective Observational Study
Mitani, K., Takahashi, T., Tokunaga, S., Inoue, T., Kanematsu, R., Minami, M., & Hanakita, J. (2023) · Neurospine · doi:10.14245/ns.2346776.388 · Cited by 24
3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate
Lewiecki, E. M., Betah, D., Humbert, L., Libanati, C. R., Oates, M. K., Shi, Y., Winzenrieth, R., Ferrari, S., & Omura, F. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae028 · Cited by 24
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China)
Tan, X., Wen, F., Yang, W., Xie, J.-Y., Ding, L., & Mo, Y. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001321 · Cited by 24
Experimental agents to improve fracture healing: utilizing the WNT signaling pathway
Haffner‐Luntzer, M. (2020) · Injury · doi:10.1016/j.injury.2020.11.051 · Cited by 24
Applications of Calcium-Based Nanomaterials in Osteoporosis Treatment
Deng, Y., Wei, W., & Tang, P. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01306 · Cited by 23
Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia
Ahn, S. H., Jung, H., Lee, E., Baek, J. Y., Jang, I., Park, S. J., Lee, J. Y., Choi, E., Lee, Y. S., Hong, S., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1428 · Cited by 23
Nanoparticle-mediated selective Sfrp-1 silencing enhances bone density in osteoporotic mice
García‐García, P., Reyes, R., García‐Sánchez, D., Pérez-Campo, F. M., Rodríguez-Rey, J. C., Évora, C., Díaz‐Rodríguez, P., & Delgado, A. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01674-5 · Cited by 23
Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
Kaneuchi, Y., Iwabuchi, M., Hakozaki, M., Yamada, H., & Konno, S. (2022) · Medicina · doi:10.3390/medicina59010019 · Cited by 23
Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis
Compston, J. E. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad029 · Cited by 23
Novel Biomarkers of Bone Metabolism
Fernández-Villabrille, S., Martín-Carro, B., Martín-Vírgala, J., Rodríguez-Santamaría, M., Baena-Huerta, F. J., Muñoz-Castañeda, J. R., Martín, J. L. F., Alonso‐Montes, C., Naves‐Díaz, M., Carrillo‐López, N., et al. (2024) · Nutrients · doi:10.3390/nu16050605 · Cited by 23
Human Genetics of Sclerosing Bone Disorders
Ridder, R. D., Boudin, E., Mortier, G. R., & Hul, W. V. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0439-7 · Cited by 23
Osteoporosis Therapeutics 2020
Kocijan, R., Klaushofer, K., & Misof, B. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_373 · Cited by 24
Executive summary of clinical practice guide on fracture risk in lifestyle diseases
Kanazawa, I., Inaba, M., Inoue, D., Uenishi, K., Saito, M., Shiraki, M., Suzuki, A., Takeuchi, Y., Hagino, H., Fujiwara, S., et al. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01149-3 · Cited by 23
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
Tai, T., Chen, H., Shih, C., Huang, C., McCloskey, E. V., Lee, J. K., Yeap, S. S., Cheung, C., Charatcharoenwitthaya, N., Jaisamrarn, U., et al. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2024.02.001 · Cited by 22
Cell membrane coated nanoparticles: cutting-edge drug delivery systems for osteoporosis therapy
Liao, J., Lü, L., Chu, X., Xiong, Y., Zhou, W., Cao, F., Peng, C. M., Shahbazi, M., Liu, G., & Mi, B. (2024) · Nanoscale · doi:10.1039/d3nr06264c · Cited by 22
Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis
Wen, F., Du, H., Ding, L., Hu, J., Huang, Z., Huang, H., Li, K., Mo, Y., & Kuang, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234123 · Cited by 22
Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
Mochizuki, T., Yano, K., Ikari, K., & Okazaki, K. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.08.001 · Cited by 22
Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis
Srivastava, A., Nogueras‐González, G. M., Geng, Y., Won, A. M., Myers, J. N., Li, Y., & Chambers, M. S. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-14 · Cited by 22
EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Osteoporosis management
Reid, I. R. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0574 · Cited by 23
Post hip fracture orthogeriatric care—a Canadian position paper addressing challenges in care and strategies to meet quality indicators
Khan, A. A., Alrob, H. A., Al-Alwani, H., Ali, D. S., Almonaei, K., Alsarraf, F., Bogoch, E. R., Dandurand, K., Gazendam, A., Juby, A. G., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06640-3 · Cited by 22
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 23
Andrographolide stimulates osteoblastogenesis and bone formation by inhibiting nuclear factor kappa-Β signaling both in vivo and in vitro
Yongyun, C., Jingwei, Z., Liu, Z., Chu, W., & Li, H. (2019) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2019.02.001 · Cited by 22
The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine
Pereira, L., & Frazão, J. M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.023 · Cited by 22
Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study
Tominaga, A., Wada, K., Kato, Y., Nishi, H., Terayama, Y., & Okazaki, K. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05639-y · Cited by 22
Anabolic treatments for osteoporosis in postmenopausal women
Hassan, N., Gregson, C. L., & Tobias, J. H. (2021) · Faculty Reviews · doi:10.12703/r/10-44 · Cited by 22
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
Hsu, C., Maddox, J., Block, G. A., Bartley, Y., & Yu, Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2050 · Cited by 21
Self-citation
Executive summary clinical practice guideline of postmenopausal, glucocortcioid-induced and male osteoporosis (2022 update). Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM)
Riancho, J. A., Peris, P., González-Macı́as, J., & Pérez‐Castrillón, J. L. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.12.008 · Cited by 21
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials ( CDM‐J )
Huang, W., Nagao, M., Yonemoto, N., Guo, S., Tanigawa, T., & Nishizaki, Y. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5594 · Cited by 21
Τhe story of sclerostin inhibition: the past, the present, and the future
Anastasilakis, A. D., & Tsourdi, E. A. (2024) · HORMONES · doi:10.1007/s42000-023-00521-y · Cited by 21
The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis
Hartz, M. C., Johannessen, F. B., Harsløf, T., & Langdahl, B. L. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae484 · Cited by 21
Drug treatment strategies for osteoporosis in stroke patients
Hsieh, C., Sung, S., & Huang, H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1736556 · Cited by 21
Associations of Serum Dickkopf‐1 and Sclerostin With Cardiovascular Events: Results From the Prospective Bruneck Study
Klingenschmid, G., Tschiderer, L., Himmler, G., Rungger, G., Brugger, S., Santer, P., Willeit, J., Kiechl, S. J., & Willeit, P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014816 · Cited by 21
Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide
Kawaguchi, H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4001 · Cited by 21
Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis
Nealy, K. L., & Harris, K. B. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020952764 · Cited by 21
Epigenetic therapies of osteoporosis
de Nigris, F., Ruosi, C., Colella, G., & Claudio Napoli, A. (2020) · Bone · doi:10.1016/j.bone.2020.115680 · Cited by 22
Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
Jeong, C., Kim, J., Lim, Y., Ha, J., Kang, M. I., & Baek, K. (2021) · Journal of Bone Metabolism · doi:10.11005/jbm.2021.28.4.317 · Cited by 21
Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses
Bastounis, A., Langley, T. E., Davis, S., Paskins, Z., Gittoes, N. J. L., Leonardi‐Bee, J., & Sahota, O. (2022) · JBMR Plus · doi:10.1002/jbm4.10620 · Cited by 21
Rheumatoid Arthritis and Osteoporosis as Prototypes of Immunosenescence in Osteoimmunology: Molecular Pathways of Inflammaging and Targeted Therapies
Aitella, E., Azzellino, G., Romano, C. P., Ginaldi, L., & Martinis, M. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199268 · Cited by 20
Glucocorticoid therapy suppresses Wnt signaling by reducing the ratio of serum Wnt3a to Wnt inhibitors, sFRP-1 and Wif-1
Kawazoe, M., Kaneko, K., & Nanki, T. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05554-x · Cited by 20
Sexing Bones: Improving Transparency of Sex Reporting to Address Bias Within Preclinical Studies
Sharma, A., Michels, L. V., Pitsillides, A. A., Greeves, J. P., Plotkin, L. I., Cardo, V., Sims, N. A., & Clarkin, C. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4729 · Cited by 21
An atlas of genetic determinants of forearm fracture
Nethander, M., Movérare‐Skrtic, S., Kämpe, A. J., Coward, E., Reimann, E., Grahnemo, L., Borbély, É., Helyes, Z., Funck‐Brentano, T., Cohen-Solal, M. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01527-3 · Cited by 20
The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment
Vachey, C., Candellier, A., Toutain, S., & Mac‐Way, F. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00858-8 · Cited by 22
Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality
Martiniaková, M., Mondočková, V., Kováčová, V., Babikova, M., Zemanová, N., Bíro, R., Pénzes, N., & Omelka, R. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01440-7 · Cited by 22
Peripheral artery disease and osteoporosis: Not only age‑related (Review)
Gaudio, A., Xourafa, A., Rapisarda, R., Castellino, P., & Signorelli, S. S. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9512 · Cited by 20
The evolving role of anabolic therapy in the treatment of osteoporosis
Cosman, F. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000616 · Cited by 20
Romosozumab in the Treatment of Osteoporosis
Kobza, A. O., Παπαϊωάννου, Α., Lau, A. N., & Adachi, J. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0158 · Cited by 20
Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes
Karsdal, M. A., Genovese, F., Rasmussen, D. G. K., Bay‐Jensen, A., Mortensen, J. H., Nielsen, S. H., Willumsen, N., Jensen, C., Manon‐Jensen, T., Jennings, L. L., et al. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.08.007 · Cited by 20
Breaking the silence: AI’s contribution to detecting vertebral fractures in opportunistic CT scans in the elderly—a validation study
Spångéus, A., Bjerner, T., Lindblom, M., Götz, C., Hummer, A., Salzlechner, C., & Woisetschläger, M. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01524-5 · Cited by 19
Cost-effectiveness of opportunistic osteoporosis screening using chest radiographs with deep learning in Germany
Reginster, J., Schmidmaier, R., Alokail, M. S., & Hiligsmann, M. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03048-x · Cited by 19
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020
CROMER, S. J., D’Silva, K. M., Yu, E. W.-Y., Landon, J. E., Desai, R. J., & Kim, S. C. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06938-8 · Cited by 19
Activation of farnesoid X receptor signaling by geniposidic acid promotes osteogenesis
Liu, M., Jin, F., Zhang, S., Li, S., Zhu, D., Cui, Y., Cai, M., Liu, X., Zhang, Y., Sun, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154258 · Cited by 19
Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease
Nagy, E., Sobh, M., Abdalbary, M., Elnagar, S., Elrefaey, R., Shabaka, S., Elshabrawy, N. A., Shemies, R. S., Tawfik, M., Santos, C. G. S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237130 · Cited by 19
Position Statement: Vitamin D Intake to Prevent Osteoporosis and Fracture in Adults
Han, A., Park, Y., Lee, Y., Park, S. Y., & Park, C. Y. (2022) · Journal of Bone Metabolism · doi:10.11005/jbm.2022.29.4.205 · Cited by 19
New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral Fractures
Skjødt, M. K., & Abrahamsen, B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad256 · Cited by 19
A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
Ong, T. I. W., Lim, L., Chan, S. P., Chee, W. S. S., Ch’ng, A. S. H., Chong, E. G. M., Damodaran, P., Hew, F. L., Ibrahim, L., Khor, H. M., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.002 · Cited by 19

Authors: Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
Affiliations: Inserm (FR)
Amgen (United States) (US)
ORCID: Saag, Kenneth G.
Petersen, Jeffrey
Brandi, Maria Luisa
Karaplis, Andrew C.
Lorentzon, Mattias
Thomas, Thierry
Maddox, Judy
Grauer, Andreas
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-10-12
Volume: 377
Issue: 15
Pages: 1417-1427
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1708322
OpenAlex: W2754720807
Cited by: 1,544
References: 31
Citations by year: 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
FWCI: 123.81
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion, other-oa)
Research Bank (Australian Catholic University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Gilead Sciences
Teva Pharmaceutical Industries
Radius Health
Medac
Chugai Pharmaceutical
Amgen Canada
UCB Pharma
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
MeSH terms: Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks